Nutrition Research
Volume 28, Issue 5 , Pages 315-320 , May 2008

Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation

  • Sherma Zibadi

      Affiliations

    • Nutritional Sciences Department, The University of Arizona, Tucson, AZ 85721, USA
    • Division of Health Promotion Sciences, Mel and Enid Zuckerman Arizona College of Public Health, The University of Arizona, Tucson, AZ 85724, USA
    • ,
  • Peter J. Rohdewald

      Affiliations

    • Institute of Pharmaceutical Chemistry, University of Münster, Münster 48149, Germany
    • ,
  • Danna Park

      Affiliations

    • Program in Integrative Medicine, Department of Medicine, The University of Arizona, Tucson, AZ 85724, USA
    • ,
  • Ronald Ross Watson

      Affiliations

    • Nutritional Sciences Department, The University of Arizona, Tucson, AZ 85721, USA
    • Sarver Heart Center, College of Medicine, The University of Arizona, Tucson, AZ 85724, USA
    • Division of Health Promotion Sciences, Mel and Enid Zuckerman Arizona College of Public Health, The University of Arizona, Tucson, AZ 85724, USA
    • Corresponding Author InformationCorresponding author. Health Promotion Sciences, PO Box 245155, The University of Arizona, Tucson, AZ 85724-5154, USA. Tel.: +1 520 626 2850; fax: +1 520 6268176.

Received 26 November 2007 ,Revised 29 February 2008 ,Accepted 7 March 2008.

References 

  1. Prevalence of diabetes. In: National Diabetes Statistics: National Diabetes Information Clearinghouse. Bethesda, MD: National Institutes of Health; 2005;
  2. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891–897
  3. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003;108:1527–1532
  4. Bakris G, Sowers J, Epstein M, Williams M. Hypertension in patients with diabetes. Why is aggressive treatment essential?. Postgrad Med. 2000;107:53–64
  5. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713–720
  6. Rohdewald PJ. Pycnogenol, French maritime pine bark extract. In:  Coates P,  Blackman MR,  Cragg G,  Levine M,  Moss J,  White J editor. Encyclopedia of dietary supplements. New York: Marcel Dekker; 2005;p. 545–553
  7. Araghi-Niknam M, Hosseini S, Larson D, Rohdewald P, Watson RR. Pine bark extract reduces platelet aggregation. Integr Med. 2000;2:73–77
  8. Devaraj S, Vega-Lopez S, Kaul N, Schonlau F, Rohdewald P, Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids. 2002;37:931–934
  9. Hosseini S, Lee J, Sepulveda RT, Rohdewald P, Watson RR. A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr Res. 2001;21:1251–1260
  10. Liu X, Zhou HJ, Rohdewald P. French maritime pine bark extract Pycnogenol dose-dependently lowers glucose in type II diabetes patients. Diabetes Care. 2004;27:839
  11. Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci. 2004;74:855–862
  12. Verma S, Anderson TJ. The ten most commonly asked questions about endothelial function in cardiology. Cardiol Rev. 2001;9:250–252
  13. Sprinthall RC. In: Basic statistical analysis. Boston: Allyn and Bacon; 2003;p. 550–565
  14. Fernandez AC, Patino R, Ibarra J, Fernandez L, Roldan M, Moya J, et al. Endothelin in hypertension and diabetes mellitus. In:  Luscher TF editors. Endothelin in cardiovascular diseases. New York: Springer; 1995;p. 157–170
  15. Blazso G, Gaspar R, Gábor M, Rüve HJ, Rohdewald P. ACE inhibition and hypotensive effect of procyanidins-containing extract from the bark of Pinus pinaster sol. Pharm Pharmacol Lett. 1996;6:8–11
  16. Fitzpatrick DF, Bing B, Rohdewald P. Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol. 1998;32:509–515
  17. Liu X, Wei J, Tan F, Zhou S, Würthwein G, Rohdewald P. Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II. Life Sci. 2004;75:2505–2513
  18. Schäfer A, Högger P. Oligomeric procyanidins of French maritime pine bark extract (Pycnogenol) effectively inhibit a-glucosidase. Diabetes Res Clin Pract. 2007;77:41–46
  19. Devaraj S, Kaul N, Schönlau F, Rohdewald P, Jialal I. Pycnogenol supplementation increases antioxidant capacity and has a favourable effect on the lipid profile in humans. Lipids. 2002;37:931–934
  20. Yang HM, Liao MF, Zhu SY, Liao MN, Rohdewald P. A randomised, double-blind, placebo-controlled trial on the effect of Pycnogenol on the climacteric syndrome in peri-menopausal women. Acta Obstet Gynecol Scand. 2007;86:978–985
  21. Nelson AB, Lau BH, Ide N, Rong Y. Pycnogenol inhibits macrophage oxidative burst, lipoprotein oxidation, and hydroxyl radical-induced DNA damage. Drug Dev Ind Pharm. 1998;24:139–144
  22. Peng Q, Wei Z, Lau BHS. Pycnogenol inhibits tumor necrosis factor-a-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci. 2000;57:834–841
  23. Grimm T, Chovanova Z, Muchova J, Sumegova K, Liptakova A, Durackova Z, et al. Inhibition of NF-kappaB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflamm (Lond). 2006;3:1
  24. Cheshier JE, ArdestaniKaboudanian S, Liang BL, Araghiniknam M, Chung SB, Lane L, et al. Immunomodulation by Pycnogenol(R) in retrovirus-infected or ethanol-fed mice. Life Sci. 1995;58:L87–L96

PII: S0271-5317(08)00060-2

doi: 10.1016/j.nutres.2008.03.003

Nutrition Research
Volume 28, Issue 5 , Pages 315-320 , May 2008

Article Tools

* Image Usage & Resolution